[1] PARKIN D M, BRAY F, FERLAY J, et al. Global cancer statisties. 2002［J］. CA: A Caneer Journal for Clinicians, 2005, 55(2): 74-108.

[2] SHERMAN M. Hepatocellular carcinoma: epidemiology, risk factors and sereening［J］. Liver Disease, 2005, 25(2), 143-154.

[3] BAGNATO V S, KURACHI C, FERREIRA J, et al. New photonic technologies for the treatment and diagnosis of Hepatic diseases: an overview of the experimental work performed in collaboration, between physics institute of Sao Carlos and ribeirao preto faculty of medicine of the university of sao paulo［J］. Acta Cir Bras, 2006, 21(Suppl 1): 3-11.

[4] ALLISON R R, SIBATA C H. Oncologic photodynamic therapy photosensitizers: a clinical review［J］. Photodiagnosis and Photodynamic Therapy, 2010, 7(2): 61-75.

[5] CHEN B T, WITTE P A. Antivascular tumor eradication by hypericin-mediated photodynamic therapy［J］. Photochemistry and Photobiology, 2002, 76(5): 509-513.

[6] KONAN Y N, GURNY R, ALLEMANN E. State of the art in the delivery of photosensitizers for photodynamic therapy［J］. Photochemistry and Photobiology, 2002, 66 (2): 89-106.

[7] SONCIN M, POLO L, REDDI E, et al. Effect of the delivery system on the biodistribution of Ge(IV) octabutoxy-phthalocyanines in tumour-bearing mice［J］. Cancer Lett, 1995, 89 (1): 101-106.

[8] XIAO FENG DENG, LI XIONG, LIANG WU LIN, et al. Photosan-II loaded hollow silica nanoparticles: Preparation and its effect in killing for QBC939 cells［J］. Photodiagnosis and Photodynamic Therapy, 2013, 10(4): 460-469.

[9] BIEL M.Advances in Photodynamic therapy for the treatment of head and neek cancers［J］. Lasers Surg Med, 2006, 38(5): 349-355.

[10] DOUGHERTY T, GOMER C, HENDERSON B, et al. Photodynamic therapy［J］. J Natl Cancer Inst, 1998, 90(2): 889-905.

[11] HATAKEYAMA H, AKITA H, HARASHIMA H. A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma［J］. Adv Drug Deliv Rev, 2011, 63 (11): 152-160.

[12] ALLISON R R, SIBATA C H. Oncologic photodynamic therapy photosensitizers: a clinical review［J］.Photodiagnosis Photodyn Ther, 2010, 7(2): 61-75.

[13] CHEN B, ROSKAMS T, WITTE P A. Antivascular tumor eradication by Hypericin-mediated photodynamic therapy［J］.Photochem Photobiol, 2002, 76(5): 509-513.

[14] GARG A D, NOWIS D, GOLAB J, et al.Immunogenic cell death, DAMPs and anticancer therapeutics: an emerging amalgamation［J］.Biochim Biophys Acta, 2010, 1805(1): 53-71.

[15] KENNEDY J C, POTTIER R H, PROSS D C. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience［J］. Photochem Photobiol B, 1990, 6(1-2): 143-148.

[16] ASCENCIO M, COLLINET P, FARINE M O, et al. Protoporphyrin IX fluorescence photobleaching is a useful tool to predict the response of rat ovarian cancer following hexaminolevulinate photodynamic therapy［J］.Lasers Surg Med, 2008, 40(2): 332-341.

[17] DE ROSA F S, BENTLEY M V. Photodynamic therapy of skin cancers: sensitizers, clinicalstudies and future directives［J］.Pharmaceutical Research, 2000, 17(12): 1447-1455.

[18] ROY I, OHULCHANSKYY T Y, PUDAVAR H E, et al. Ceramic-basednanoparticles entrapping water-insoluble photosensitizinganticancer drugs: a novel drug-carrier system for photody-namic therapy［J］. Journal of the American Chemical Society, 2003, 125(26): 7860-7865.

[19] WANG S Z, GAO R M, ZHOU F M, et al. Nanomaterialsand signlet oxygen photosensitizers: potential applicationsin photodynamic therapy［J］. Journal of Materials Chemistry, 2004, 14(4): 487-493.

[20] HAMBLIN M R, NEWMAN E L. On the mechanism of the tumour-localising effect in photodynamic therapy［J］. Photochem Photobiol B, 1994, 23(1): 3-8.